TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05739162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Endoscopic Suture System
Description: Endoscopic Sleeve Gastroplasty (ESG), and endoscopic minimally-invasive weight loss procedure, utilizing a suturing device to reduce the stomach volume by 70-80% through the creation of sleeve. This is accomplished by a series of endoscopically placed stitches through the stomach wall.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Low-calorie healthy diet personalized by a dietician according to individual patients' needs and conducive to weight loss. Physical activity will be encourage and assessed.
Study: NCT05557591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT116
Description: BNT116 is administered by IV injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is administered Q3W by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is administered Q3W by IV infusion
Study: NCT06327256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202
Study: NCT06116435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.
Study: NCT06327256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3000202
Description: BI 3000202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching BI 3000202
Study: NCT06116435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Participants will receive access to positive mental guided imagery recordings. Recordings describe a pleasant experience while walking and range from 2-8 minutes in duration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 1:1 Support
Description: Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 1:1 Support
Description: Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 1:1 Support
Description: Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 1:1 Support
Description: Participants will meet individually with their class instructor to receive personalized recommendations on how to incorporate messages from the Move group-based classes into their daily lives. Sessions are based on Self-Determination Theory and will last approximately 45 minutes.
Study: NCT06327256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching BI 3000202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching BI 3000202
Study: NCT06374251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in narrative medicine sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05670353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Derivatives
Description: CBD 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10 mg (up-titrated until 150mg or adverse effects) daily for 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal Contraceptive Agents
Description: All participants will be given hormonal contraceptive.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hormonal Contraceptive Agents
Description: All participants will be given hormonal contraceptive.
Study: NCT06321627

Intervention type: RADIATION
Intervention: Radiation therapy as curative treatment
Description: Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
Study: NCT06327256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching BI 3000202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam
Study: NCT05860868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 cycles induction chemotherapy
Description: Drug: 2 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 cycles induction chemotherapy
Description: Drug: 3 cycles Induction Chemotherapy Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.~Drug: Concurrent Chemotherapy Cisplatin 100 mg/m², Q3w.~Radiation: Definitive Radiotherapy For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Study: NCT05437835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 20 ml injection into the subparaneural space of sciatic nerve
Study: NCT05124236

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preoperative radiosurgery
Description: single fraction radiosurgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: postoperative hypofractionated stereotactic radiotherapy
Description: 5 fraction stereotactic radiotherapy /fractionated radiosurgery
Study: NCT05839821

Intervention type: BEHAVIORAL
Intervention: noF-noRAS
Description: resting state, that is, without finger-tapping and without listening to RAS

Intervention type: BEHAVIORAL
Intervention: noF-noRAS
Description: resting state, that is, without finger-tapping and without listening to RAS

Intervention type: BEHAVIORAL
Intervention: F-noRAS
Description: finger-tapping without listening to RAS

Intervention type: BEHAVIORAL
Intervention: F-noRAS
Description: finger-tapping without listening to RAS

Intervention type: BEHAVIORAL
Intervention: noF-100RAS
Description: listening to RAS with the 100% of the baseline tempo and without finger-tapping

Intervention type: BEHAVIORAL
Intervention: noF-100RAS
Description: listening to RAS with the 100% of the baseline tempo and without finger-tapping

Intervention type: BEHAVIORAL
Intervention: F-100RAS
Description: finger-tapping and listening to RAS with 100 % of baseline tempo

Intervention type: BEHAVIORAL
Intervention: F-100RAS
Description: finger-tapping and listening to RAS with 100 % of baseline tempo

Intervention type: BEHAVIORAL
Intervention: F-105RAS
Description: finger-tapping and listening to RAS with 105 % of baseline tempo

Intervention type: BEHAVIORAL
Intervention: F-105RAS
Description: finger-tapping and listening to RAS with 105 % of baseline tempo

Intervention type: BEHAVIORAL
Intervention: F-110RAS
Description: finger-tapping and listening to RAS with 110 % of baseline tempo

Intervention type: BEHAVIORAL
Intervention: F-110RAS
Description: finger-tapping and listening to RAS with 110 % of baseline tempo
Study: NCT06164197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Robot Assisted Gait Training
Study: NCT04576936

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AIRVO
Description: Daily, at-home device use of AIRVO device in moderate to severe COPD patients.
Study: NCT04721145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitor
Description: Eligible patients will have a Dexcom G6 Continuous Glucose Monitor placed for 10 days.
Study: NCT06655337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application for Post-Discharge Symptom Monitoring
Description: This intervention involves the use of a smartphone application designed for symptom monitoring. The app enables participants to log daily health data, including symptoms and vital signs, for 7 days following discharge. It provides automated prompts and guidance for self-management, including when to seek medical assistance. The app does not provide direct medical intervention but facilitates remote symptom tracking to reduce readmissions and emergency hospitalizations. Follow-up consultations are conducted at day 7 and day 28.
Study: NCT06377007

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOLMaster 700 (Carl Zeiss Meditec AG)
Description: Subjects will undergo measurements with the IOLMaster 700 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argos (Alcon Laboratories, Inc.)
Description: Subjects will undergo measurements with the Argos device.
Study: NCT04878211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 3 loading doses followed by monthly administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 3 loading doses followed by monthly administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 3 loading doses followed by monthly administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: 3 loading doses followed by monthly administrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon or glatiramer acetate
Description: iDMT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon or glatiramer acetate
Description: iDMT
Study: NCT06164197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thera Trainer Balo
Description: Virtual Reality Based Balance Training Device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-Specific Rehabilitation Program
Description: Person-Specific Rehabilitation Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-Specific Rehabilitation Program
Description: Person-Specific Rehabilitation Program
Study: NCT04778371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 64 g total dry roasted, unsalted almonds per day for a total of 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 g total calorie matched granola bar per day for total of 12 weeks
Study: NCT05564845

Intervention type: DIAGNOSTIC_TEST
Intervention: MR scan of the brain
Description: Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.
Study: NCT06049134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV20
Description: Given by Injection into the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV20
Description: Given by Injection into the muscle
Study: NCT05797311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Description: Proprioceptive Neuromuscular Facilitation (PNF) techniques are a therapeutic exercise approach developed based on functional activities in daily life. At the stage of regaining movement and function, it creates models similar to functional activities.

Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder Stabilization Exercises
Description: Scapular stabilization exercise and stabilization exercise for the shoulder joints
Study: NCT05270824

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radical surgery after neoadjuvant immunotherapy
Description: A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: radical surgery after neoadjuvant chemotherapy
Description: A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
Study: NCT05564845

Intervention type: DIAGNOSTIC_TEST
Intervention: MR scan of the brain
Description: Subjects will undergo MRI of the head, blood sampling and neurological examination on the same day or spread over 2 days. On a separate day from blood sampling and undergoing an MRI scan, the neuropsychological assessment will take place. The interval between the MRI scan and the neuropsychological assessment will be a maximum of 2 months. These measurements will be performed a total of 3 times with an interval of 2 years.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood work
Description: Lab work for current lab values and biobanking

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood work
Description: Lab work for current lab values and biobanking

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological examination
Description: Classical neurological examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological examination
Description: Classical neurological examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~* Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~* A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~  * Narrative memory~ * Word fluency~ * Route finding NEPSY-II~* World Fluency~* Additional Questionnaires (6-18 years):~  * Child Behavior Checklist (CBCL)~ * Teacher Report Form (TRF)~ * Youth Self Report (YSR)~ * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~ * Conners-3® • Additional Questionnaires (18+ years):~ * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70)~ * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70)~ * Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Overview of standard neurocognitive assessment tools in BRICK study Children and adolescents (Young) Adults~* Wechsler Intelligence Test for Children- Fifth edition (WISC-V) (6-16 YOA) Wechsler Adult Intelligence Scale- Fourth edition WAIS-IV (16-24 YOA)~* A Developmental NEuroPSYchological Assessment, Second Edition (NEPSY-II)~  * Narrative memory~ * Word fluency~ * Route finding NEPSY-II~* World Fluency~* Additional Questionnaires (6-18 years):~  * Child Behavior Checklist (CBCL)~ * Teacher Report Form (TRF)~ * Youth Self Report (YSR)~ * Behavior Rating Inventory of Executive Function (BRIEF), parent- and teacher-report)~ * Conners-3® • Additional Questionnaires (18+ years):~ * Adult Self-Report (ASR) / Adult Behavior Checklist (ABCL) (in case of IQ\<70)~ * Behavior Rating Inventory of Executive Function Adult version (BRIEF-A), self-report / informant-report (in case of IQ\<70)~ * Conners' Adult ADHD Rating Scales (CAARS)~Emma toolbox
Study: NCT05830461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychological care program to reduce psychological distress in women who attend a breast clinic
Description: The intervention will be online and self-applied. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological care program to reduce psychological distress in women who attend a breast clinic
Description: The intervention will be delivered through printed materials. It will consist of 3 stages, according to the patient's situation: 1) without suspicion of cancer (A1), 2) with suspicion of cancer (A2), and 3) with confirmed diagnosis of cancer (B).~Stage 1 includes modules related to the prevention and timely detection of breast cancer. Stage A2 consists of emotional management in the face of suspicion of breast cancer. In stage B, medical information about breast cancer is provided, as well as psychological strategies to face the diagnosis.~Psychological techniques based on the cognitive behavioral model, mindfulness, acceptance and commitment therapy, and health beliefs are included.
Study: NCT05675774

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual Energy CT
Description: Patients with acute stroke who receive intervention will undergo dual-energy CT in lieu of single-energy CT at 24 hours post-intervention.
Study: NCT06331650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
Study: NCT05452213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion.
Study: NCT04561414

Intervention type: DEVICE
Group type: OTHER
Intervention: LED light source system for endoscope
Description: The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ureteral stent (Cook Ireland Ltd.)
Description: The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
Study: NCT06556030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Botulinum Toxin
Study: NCT06467032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: superficial CO2 laser resurfacing
Description: Application of the tested product and comparators on the laser treated side of the back

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser untreated side
Description: Application of the tested product and comparators on the laser untreated (control) side of the back
Study: NCT06556030

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: Saline Solution
Study: NCT05248360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen-oxygen mixed gas(H2-O2) inhalation
Description: H2-O2 inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Air inhalation
Description: Air inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)